Iranian Journal of Pediatrics

Published by: Kowsar

High-Dose Oral Ibuprofen in Treatment of Patent Ductus Arteriosus in Full-Term Neonates

Shahnaz Pourarian 1 , Mehrdad Rezaie 1 , Hamid Amoozgar 2 , * , Ali-Mohammad Shakiba 2 , Mohammad-Reza Edraki 2 and Nima Mehdizadegan 2
Authors Information
1 Department of Pediatrics, Neonatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Cardiac and Neonatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Iranian Journal of Pediatrics: August 28, 2015, 25 (4); e2005
  • Published Online: August 24, 2015
  • Article Type: Research Article
  • Received: April 16, 2015
  • Accepted: April 27, 2015
  • DOI: 10.5812/ijp.2005

To Cite: Pourarian S, Rezaie M, Amoozgar H, Shakiba A, Edraki M, et al. High-Dose Oral Ibuprofen in Treatment of Patent Ductus Arteriosus in Full-Term Neonates, Iran J Pediatr. 2015 ;25(4):e2005. doi: 10.5812/ijp.2005.

Abstract
Copyright © 2015, Growth & Development Research Center.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Allen HD, Driscoll DJ, Shaddy RE, Feltes T. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 2007;
  • 2. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998; 50(1): 35-58[PubMed]
  • 3. Thebaud B, Michelakis ED, Wu XC, Moudgil R, Kuzyk M, Dyck JR, et al. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation. 2004; 110(11): 1372-9[DOI][PubMed]
  • 4. Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med. 2002; 8(2): 91-2[DOI][PubMed]
  • 5. Loftin CD, Trivedi DB, Langenbach R. Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest. 2002; 110(4): 549-57[DOI][PubMed]
  • 6. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature. 1997; 390(6655): 78-81[DOI][PubMed]
  • 7. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun. 1998; 246(1): 7-12[DOI][PubMed]
  • 8. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39(12): 1890-900[PubMed]
  • 9. Mullins CE. The Science and Practice of Pediatric Cardiology. 1990; : 1055–6
  • 10. Milliken JC, D'Souza G. Patent Ductus Arteriosus. Review Article eMedicine cardiology. 2007; 115(8): 1039-50
  • 11. Madan JC, Kendrick D, Hagadorn JI, Frantz I3, National Institute of Child H, Human Development Neonatal Research N. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009; 123(2): 674-81[DOI][PubMed]
  • 12. Benjamin JR, Smith PB, Cotten CM, Jaggers J, Goldstein RF, Malcolm WF. Long-term morbidities associated with vocal cord paralysis after surgical closure of a patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2010; 30(6): 408-13[DOI][PubMed]
  • 13. Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. Pediatr Cardiol. 2010; 31(1): 40-3[DOI][PubMed]
  • 14. Timethy M, Hugh D. , Allen DJ, Driscoll RES. Physiology of the preterm and term infant. Moss and Adams' Heart Disease in Infants, Children, and Adolescents. 2008; : 440-1
  • 15. Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J. 1977; 39(6): 610-8[PubMed]
  • 16. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics. 1978; 62(5): 706-12[PubMed]
  • 17. Watanabe K, Tomita H, Ono Y, Yamada O, Kurosaki K, Echigo S. Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects. Circ J. 2003; 67(9): 750-2[PubMed]
  • 18. Takami T, Yoda H, Kawakami T, Yamamura H, Nakanishi T, Nakazawa M, et al. Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol. 2007; 28(1): 46-50[DOI][PubMed]
  • 19. Rudolph AM. Congenital Disease of The Heart. 2001; : 155-96
  • 20. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995; 127(3): 466-71[PubMed]
  • 21. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005; 164(3): 135-40[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments